Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 27, 1997

View Archived Issues

Dusa announces initiation of bladder cancer photodetection study and Q3 1997 highlights

Cytogen: Q3 1997 highlights

Immunomedics: Q1 1998 highlights

Alpharma: Q3 1997 highlights

New erythromycins discovered at Roussel Uclaf

Genetronics cleared to start electroporation therapy phase II trial in U.S.

Clinical efficacy of naltrexone demonstrated in patients with cholestatic pruritus

Cephalon and TAP renew oncology collaboration

Stress proteins shown to activate CTL response to cancer cells

Ono accelerates overseas development of neurologic drug

Beaufour-Ipsen moves TH-9506 to phase I

Ono's elastase inhibitor poised to enter phase I in Europe

AnorMED's AMD-473 enters phase I

New V1 antagonists disclosed by Yamanouchi

WB-2663B, a novel immunosuppressant isolated from Pseudomonas

Agents activating beta3-adrenoceptors from Pfizer

Cathepsin L inhibitors with broad therapeutic potential from Takeda

Pharmacological profile of TH-142177, a new AT1 receptor antagonist

Abbott improves on the pharmacological profiles of its ChCM candidates

SB-205384 associated with temporal modulation of GABA-gated currents

Profile of hepatoprotective activity of picroliv in rats

Controlled trial of ofloxacin + IFN-alpha-2b in chronic hepatitis C

Tolcapone reduces "wearing-off" phenomonen in Parkinson's disease patients

RPR merger with Rhone-Poulenc finalized

Launch of Ligand/Lilly metabolic disease alliance

FACT study results reported

FDA clears Zomig

First anticancer monoclonal antibody approved by FDA

Bronchodilating mechanism of PDE IV inhibitors investigated using CP-80633

SmithKline Beecham and Cephalon terminate calpain inhibitor collaboration

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 16, 2025.
Zusduri flurry ends; ‘set up’ at ODAC, Urogen prevails with FDA
BioWorld
During a conference call after the U.S. FDA approval of Zusduri (mitomycin), Urogen Pharma Ltd. CEO Liz Barrett offered candid observations about a...
23andme founder-led group outbids Regeneron for company
BioWorld
The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing company in a bidding battle against...
Elevidys’ second liver death hits Sarepta, sends DMD ripples
BioWorld
How the U.S. FDA might respond became a serious question for Wall Street as Sarepta Therapeutics Inc. made known a second death due to acute liver failure with...